Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01195 ...
Drug Name Flecainide
Molecular Weight 414.3427
Molecular Formula C17H20F6N2O3
CAS Number 54143-55-4
SMILES FC(F)(F)COC1=CC(C(=O)NCC2CCCCN2)=C(OCC(F)(F)F)C=C1
External Links
DRUGBANK DB01195
T3DB T3D2556
PubChem Compound 3356
PDR 3476
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 3.78 - 3.78 - MANNHOLD,R ET AL. (1990)
Melting Point 228.5 ℃ 228-229 ℃ Bmitt, E.H. and Brown, W.R.; U.S. Patent 3,900,481; August 19,1975; assigned to Riker Laboratories, Inc.
Water Solubility 48400.0 mg/L 48.4 mg/ml FDA Label
pKa 9.3 - 9.3 - FDA Label

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 90.0 % 90 % PO, oral; DRUGBANK
Bioavailability 70.0 % 70±11 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 458.0 ng/ml 458±100 ng/ml PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 3.5 h 3-4 h PO, oral; DRUGBANK
T Max 3.0 h ~3(1-6) h PO, oral; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 0.50 L/h/kg 4.6-12.1 ml/min/kg Average clearance; intravenous injection, IV; Male, men; DRUGBANK
Clearance 0.72 L/h/kg 4.0-20 ml/min/kg Average clearance; PO, oral; DRUGBANK
Clearance 0.34 L/h/kg 5.6±1.3 ml/min/kg hydrolysis; Children ↑ ;Hepatic cirrhosis, cirr ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ;congestive heart disease ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.29 L/h/kg 4.9 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 9.2 L/kg 5-13.4 L/kg Average volume of distribution; Male, men; DRUGBANK
Volume of Distribution 4.9 L/kg 4.9±0.4 L/kg Apparent volume of distribution; Hepatic cirrhosis, cirr ↑ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 6.1 L/kg 6.1 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 13.0 h 13 h normal,healthy; DRUGBANK
Half-life 16.0 h 16 h Oral multiple dose; normal,healthy; DRUGBANK
Half-life 20.0 h 20 h ventricular premature complex; patients; DRUGBANK
Half-life 12.6 h 12.6 h DRUGBANK
Half-life 11.0 h 11±3 h hydrolysis; Children ↓ ;RD, renal impairment, Renal disease，including uremia ↑ ;Hepatic cirrhosis, cirr ↑ ;congestive heart disease ↑ ; The Pharmacological Basis of Therapeutics
Half-life 12.0 h 12 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 1346.0 mg/kg 1346.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 170.0 mg/kg 170.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 215.0 mg/kg 215.0 mg/kg intravenous injection, IV; Rattus, Rat; DRUGBANK
Toxicity LD50 188.0 mg/kg 188.0 mg/kg intravenous injection, IV; mouse; DRUGBANK
Toxicity LD50 274.0 mg/kg 50-498 mg/kg PO, oral; Rattus, Rat; T3DB
Toxicity TDLo 20.0 mg/kg 20.0 mg/kg PO, oral;  Female, women; DRUGBANK
Toxicity TDLo 40.0 mg/kg 40.0 mg/kg PO, oral; Male, men; DRUGBANK
Eliminate Route 86.0 % ~86 % Urinary excretion; Oral single dose; DRUGBANK
Eliminate Route 5.0 % 5 % Faeces excretion; Oral single dose; DRUGBANK
Eliminate Route 36.1 % 36.12 % Urinary excretion; Oral single dose; Unchanged drug; DRUGBANK
Eliminate Route 43.0 % 43±3 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 40.0 % 40 % DRUGBANK
Protein Binding 61.0 % 61±10 % myocardial infarction ↓ ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for infants 200.0 mg/m2/day 200 mg/m2/day PO, oral Flecainide Acetate flecainide acetate PDR
Max dose for children 200.0 mg/m2/day 200 mg/m2/day PO, oral Flecainide Acetate flecainide acetate PDR
Max dose for adolescents 300.0 mg/day 300 mg/day PO, oral Flecainide Acetate flecainide acetate PDR
Max dose for adolescents 400.0 mg/day 400 mg/day PO, oral Flecainide Acetate flecainide acetate PDR
Max dose for adults 300.0 mg/day 300 mg/day PO, oral Flecainide Acetate flecainide acetate PDR
Max dose for adults 400.0 mg/day 400 mg/day PO, oral Flecainide Acetate flecainide acetate PDR
Max dose for elderly 300.0 mg/day 300 mg/day PO, oral Flecainide Acetate flecainide acetate PDR
Max dose for elderly 400.0 mg/day 400 mg/day PO, oral Flecainide Acetate flecainide acetate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1